# Clinical Trial Phase I/II Prospective, Open Nonrandomized for Treatmen of Postoperative Air Leak After Lung Resection in High Risk Patients Through the Administration of Mesenchymal Autologous Cells

> **NCT02045745** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Red de Terapia Celular** · enrollment: 10 (estimated)

## Conditions studied

- Postoperative Air Leaks in Risk Patients

## Interventions

- **BIOLOGICAL:** Implantation of autologous mesenchymal stem cells (CSM) expanded "in vitro" and administered directly into the lung suture line

## Key facts

- **NCT ID:** NCT02045745
- **Lead sponsor:** Red de Terapia Celular
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-12
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2017-03-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02045745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02045745, "Clinical Trial Phase I/II Prospective, Open Nonrandomized for Treatmen of Postoperative Air Leak After Lung Resection in High Risk Patients Through the Administration of Mesenchymal Autologous Cells". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02045745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*